BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 37047025)

  • 21. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell Type-Specific Induction of Inflammation-Associated Genes in Crohn's Disease and Colorectal Cancer.
    Saul D; Leite Barros L; Wixom AQ; Gellhaus B; Gibbons HR; Faubion WA; Kosinsky RL
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease.
    Matsuoka K; Hamada S; Shimizu M; Nanki K; Mizuno S; Kiyohara H; Arai M; Sugimoto S; Iwao Y; Ogata H; Hisamatsu T; Naganuma M; Kanai T; Mochizuki M; Hashiguchi M
    PLoS One; 2018; 13(10):e0204632. PubMed ID: 30286108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigating regulatory patterns of NLRP3 Inflammasome features and association with immune microenvironment in Crohn's disease.
    Wu H; Zeng R; Qiu X; Chen K; Zhuo Z; Guo K; Xiang Y; Yang Q; Jiang R; Leung FW; Lian Q; Sha W; Chen H
    Front Immunol; 2022; 13():1096587. PubMed ID: 36685554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of CD40 and its ligand, CD40L, in intestinal lesions of Crohn's disease.
    Battaglia E; Biancone L; Resegotti A; Emanuelli G; Fronda GR; Camussi G
    Am J Gastroenterol; 1999 Nov; 94(11):3279-84. PubMed ID: 10566730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of RANTES expression in Crohn's disease and ulcerative colitis: an aid in the differential diagnosis?
    Ansari N; Abdulla J; Zayyani N; Brahmi U; Taha S; Satir AA
    J Clin Pathol; 2006 Oct; 59(10):1066-72. PubMed ID: 16565224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.
    Pedersen G
    Dan Med J; 2015 Jan; 62(1):B4973. PubMed ID: 25557335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comprehensive review and update on Crohn's disease.
    Gajendran M; Loganathan P; Catinella AP; Hashash JG
    Dis Mon; 2018 Feb; 64(2):20-57. PubMed ID: 28826742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic determinants associated with early age of diagnosis of IBD.
    Connelly TM; Berg AS; Harris L; Brinton D; Deiling S; Koltun WA
    Dis Colon Rectum; 2015 Mar; 58(3):321-7. PubMed ID: 25664710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of NOX1, a superoxide-generating NADPH oxidase, in colon cancer and inflammatory bowel disease.
    Szanto I; Rubbia-Brandt L; Kiss P; Steger K; Banfi B; Kovari E; Herrmann F; Hadengue A; Krause KH
    J Pathol; 2005 Oct; 207(2):164-76. PubMed ID: 16086438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natalizumab for induction of remission in Crohn's disease.
    Macdonald JK; McDonald JW
    Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interleukin 16 expression and phenotype of interleukin 16 producing cells in Crohn's disease.
    Middel P; Reich K; Polzien F; Blaschke V; Hemmerlein B; Herms J; Korabiowska M; Radzun HJ
    Gut; 2001 Dec; 49(6):795-803. PubMed ID: 11709514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNAs as Innovative Biomarkers for Inflammatory Bowel Disease and Prediction of Colorectal Cancer.
    Masi L; Capobianco I; Magrì C; Marafini I; Petito V; Scaldaferri F
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted
    Notararigo S; Martín-Pastor M; Viñuela-Roldán JE; Quiroga A; Dominguez-Munoz JE; Barreiro-de Acosta M
    J Mol Med (Berl); 2021 Sep; 99(9):1251-1264. PubMed ID: 34021361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Whole genome gene expression meta-analysis of inflammatory bowel disease colon mucosa demonstrates lack of major differences between Crohn's disease and ulcerative colitis.
    Granlund Av; Flatberg A; Østvik AE; Drozdov I; Gustafsson BI; Kidd M; Beisvag V; Torp SH; Waldum HL; Martinsen TC; Damås JK; Espevik T; Sandvik AK
    PLoS One; 2013; 8(2):e56818. PubMed ID: 23468882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natalizumab for induction of remission in Crohn's disease.
    MacDonald JK; McDonald JW
    Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease.
    Satsangi J; Welsh KI; Bunce M; Julier C; Farrant JM; Bell JI; Jewell DP
    Lancet; 1996 May; 347(9010):1212-7. PubMed ID: 8622450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of platelet-related subtypes and diagnostic markers in pediatric Crohn's disease based on WGCNA and machine learning.
    Tang D; Huang Y; Che Y; Yang C; Pu B; Liu S; Li H
    Front Immunol; 2024; 15():1323418. PubMed ID: 38420127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Highly Multiplexed Image Analysis of Intestinal Tissue Sections in Patients With Inflammatory Bowel Disease.
    Kondo A; Ma S; Lee MYY; Ortiz V; Traum D; Schug J; Wilkins B; Terry NA; Lee H; Kaestner KH
    Gastroenterology; 2021 Dec; 161(6):1940-1952. PubMed ID: 34529988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.